Compare MMA & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | CLGN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Australia | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 18.4M |
| IPO Year | 2024 | N/A |
| Metric | MMA | CLGN |
|---|---|---|
| Price | $1.12 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 282.7K | 40.0K |
| Earning Date | 01-01-0001 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $739,641.00 | ★ $2,475,000.00 |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | $85.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 191.30 | ★ 280.77 |
| 52 Week Low | $0.60 | $1.30 |
| 52 Week High | $3.07 | $4.98 |
| Indicator | MMA | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 40.15 |
| Support Level | $1.08 | $1.37 |
| Resistance Level | $1.25 | $1.60 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 23.03 | 56.34 |
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.